Hikma given shot in the arm by ‘excellent’ double-digit growth Business Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]
Hikma: Pharma giant starts year strong as new product sales surge in key markets pharma In 2023, the group became the second-largest pharmaceutical company in Middle East and North Africa by sales.
Hikma shares spike after pharma giant’s profit up 30 per cent hIKMA Mishlawi said the firm "has a resilient portfolio of diversified global businesses that are expanding to meet growing regional needs for a broad range of essential medicines."
Hikma makes strong start to year, receives approval for opioid treatment April 30, 2021 Hikma Pharmaceuticals today said it has received approval to launch its new KLOXXADO nasal spray for the emergency treatment of opioid overdose. Delivering a trading update, the company reported a strong start to 2021, helped by its injectables, generics and branded divisions meeting expectations. Hikma expects its full year generics revenue to be towards the [...]
Hikma Pharmaceuticals sees revenue soar on strong demand for Covid treatment drugs February 25, 2021 London-based Hikma Pharmaceuticals has said it expects a huge rise in annual core operating profit for the year, after being called in to supply emergency drugs for Covid patients during the pandemic. The FTSE 100–listed company, which supplies generic drugs including anaesthetics, pain medications and sedatives, said core operating profit jumped 11 per cent to [...]
Easyjet and Marks and Spencer candidates for relegation in FTSE reshuffle June 2, 2019 Easyjet looks set to be the next company to fall out of the FTSE 100, with several others, including Marks and Spencer, nervously eyeing the drop ahead of the blue chip list’s reshuffle on Wednesday. The budget carrier has faced a turbulent time, which has pushed shares down 22 per cent in the last six [...]
Best 25 stocks in the last tax year April 15, 2019 | City Talk By Graeme Evans from interactive investor. The FTSE 100 outperformed mid-caps last tax year, but the top FTSE 350 performers might surprise you. Take a look at the financial year ended on the 5th April, with the 25 top performing stocks in the FTSE 350 all producing gains of 40 per cent or more over the [...]
City Moves for 5 October 2018 – who’s switching jobs at Hikma Pharmaceuticals, Evestment, Nucleus and City AM? October 5, 2018 Today's City Moves covers pharma, investment, IT and City Moves. Take a look at these movers and shakers: Hikma Pharmaceuticals Hikma Pharmaceuticals has appointed Sagar Patel to a newly created London-based role as the European commercial head for its injectables business. Sagar joins Hikma at a time of organisational change to boost the group’s senior [...]
FTSE 100 and 250 quarterly review takes effect as Hikma, Tullow Oil and Afren shuffle March 23, 2015 The shake-up revealed as a result of the quarterly review of the FTSE 100 and 250 takes effect this morning. Hikma Pharmaceuticals entered the blue-chip benchmark index, and its shares were down 2 per cent at £21.40. The pharmaceutical products manufacturer, which floated around ten years ago, has a market cap of £4.22bn. Hikma knocked out Tullow Oil [...]
FTSE 100 and 250 promotions and relegations: Tullow Oil, Afren set to slip after quarterly review March 2, 2015 Tullow Oil and Afren are likely to slip out of their respective FTSE indexes after this week's quarterly review. Analysis by Société Générale said Tullow Oil could fall out of the FTSE 100. The Irish firm recently reported a £1.3bn pre-tax loss, its first in 15 years, having revealed a $2.3bn (£1.5bn) write-off in January. [...]